Supplier News Breaks Archives
AstraZeneca, Bristol-Myers alliance funds diabetes research
January 16th, 2014
WILMINGTON, Del., and PRINCETON, N.J. – Through their U.S. Diabetes Alliance, AstraZeneca and Bristol-Myers Squibb Co. are making a three-year grant to the American Diabetes Association's "Pathway to Stop Diabetes" program.
The pharmaceutical companies said Thursday that the $5 million grant will provide significant resources and support for a new generation of diabetes researchers, generating discoveries through innovation, collaboration and radical thinking.
AstraZeneca and Bristol-Myers noted that a need for a broader approach to diabetes management has been recognized by policymakers, professional societies and advocacy organizations, given that the progressive disease requires a range of treatment options and guidelines for individualized care.
And while diabetes affects 25.8 million Americans, the National Institutes of Health (NIH) reports much lower funding for diabetes research than other diseases, such as cancer and HIV/AIDS.
The 2013 Pathway Awards will provide $1.625 million in support for five to seven years for the selected investigators and will fund research relevant to any diabetes type, diabetes-related disease state or diabetes complication. Nominations included a wide range of disciplines, including medicine, biology, chemistry, engineering, physics and mathematics.
"The AstraZeneca/Bristol-Myers Squibb Diabetes Alliance recognizes the need for a broader approach to diabetes management and is proud to work with the American Diabetes Association on Pathway to Stop Diabetes," commented Rich Daly, president of the companies' U.S. Diabetes Alliance. We look forward to following the progress of the 2013 Pathway Awards researchers as they work to discover innovative treatment options and solutions to address a wide range of needs for patients living with the many burdens of diabetes."
Last month, the companies announced that AstraZeneca will acquire Bristol-Myers' interest in their U.S. Diabetes Alliance to consolidate global ownership of the diabetes business within AstraZeneca. The agreement is expected to close during the 2014 first quarter.